Skip to main content
FinSpry Logo
FinSpry
CNTB logo
CNTB
(NASDAQ)
Connect Biopharma Holdings Limited
$2.07-- (--)
Loading... - Market loading
OverviewFinancialsForecastStatisticsDividendsHistoricalProfile

Connect Biopharma Holdings (CNTB) Company Profile

Complete business overview, executive team, trading details, and corporate information.

Connect Biopharma Holdings Limited
CNTB•Nasdaq Stock Market•Healthcare•Biotechnology

About Connect Biopharma Holdings

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Rα in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOBarry Quart
Founded2012
IPO DateMarch 19, 2021
Employees64
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNasdaq Stock Market (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Websitewww.connectbiopharm.com
Phone877 245 2787
Address
3580 Carmel Mountain Road, Suite 200 San Diego, California 92130 United States

Corporate Identifiers

CIK0001835268
CUSIPG23549101
ISINKYG235491019
SIC2834

Leadership Team & Key Executives

Dr. Barry D. Quart Pharm.D.
Chief Executive Officer and Director
David L. Szekeres J.D.
President
Lisa Peraza CPA
Senior Vice President of Finance
Jeff Cohn J.D.
General Counsel and Corporate Secretary
Sean T. Ristine
Vice President of Human Resources
Dr. Lei Sun Ph.D.
Vice President of Biologics and Head of CMC
Dr. Srikanth Pendyala M.D.
Senior Vice President of Clinical Development(Consultant)
Kimberly J. Manhard
Executive Vice President and Chief Development Officer